Cantel Medical To Join S&P SmallCap 600 Index
November 13 2009 - 9:17AM
PR Newswire (US)
LITTLE FALLS, N.J., Nov. 13 /PRNewswire-FirstCall/ -- CANTEL
MEDICAL CORP. (NYSE:CMN) announced today that it will be added to
the S&P SmallCap 600 Index on a date to be announced by
Standard & Poor's. This index covers approximately 3% of the
domestic equities market and is designed to be an efficient
portfolio of companies that meet specific inclusion criteria to
ensure that they are investable and financially viable. Cantel's
President and CEO, Andrew Krakauer stated, "We are pleased that the
S&P Index Committee has selected us for inclusion in the
S&P SmallCap 600. This listing recognizes our market
capitalization, financial viability, public float and strong
liquidity and provides us with additional visibility as a market
leader in the healthcare industry." Criteria for addition to the
S&P SmallCap 600 Index includes a market capitalization in the
range of $200 million to $1 billion, four consecutive quarters of
positive GAAP Net Income, a public float of at least 50% and a
ratio of annual dollar value traded to market capitalization of
0.30 or greater. About Cantel Medical Corp. Cantel Medical Corp.
(NYSE:CMN) is a leading provider of infection prevention and
control products in the healthcare market. Our products include
specialized medical device reprocessing systems for renal dialysis
and endoscopy, dialysate concentrates and other dialysis supplies,
disposable infection prevention and control products primarily for
the dental industry, water purification equipment, sterilants,
disinfectants and cleaners, hollow fiber membrane filtration and
separation products for medical and non-medical applications, and
specialty packaging for infectious and biological specimens. We
also provide technical maintenance for our products and offer
compliance training services for the transport of infectious and
biological specimens. For more information please visit
http://www.cantelmedical.com/. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve
a number of risks and uncertainties, including, without limitation,
the risks detailed in Cantel's filings and reports with the
Securities and Exchange Commission. Such forward-looking statements
are only predictions, and actual events or results may differ
materially from those projected or anticipated. DATASOURCE: Cantel
Medical Corp. CONTACT: Andrew A. Krakauer, President and CEO,
Cantel Medical Corp., +1-973-890-7220; or Richard E. Moyer, Cameron
Associates, Inc., , +1-212-554-5466 Web Site:
http://www.cantelmedical.com/
Copyright
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jul 2023 to Jul 2024